News and Information Related to Cancer. Read about Colon, Lung, Prostate, Skin and many other forms of Cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Clues to Preventing Return of Liver Cancer

Small study finds antiviral therapy halts recurrence in patients with chronic hepatitis B

TUESDAY, June 29 (HealthDay News) -- Antiviral therapy may halt or slow recurrence of liver cancer in patients with chronic hepatitis B and extend their lives, finds a new study.

Previous research has shown that antiviral therapy reduces the incidence of liver cancer in such patients.

Advertisement
Related Stories
 border=
U.S. Database of Breast Cancer Treatment May Be Inaccurate
Experimental Vaccine Seems to Cure Prostate Cancer in Mice
Dads Can Light Their Grills Without Fear
Related Videos
 border=
Tumor Detecting App: Medicine's Next Big Thing?
Powerful Combo Reducing Lymphedema
Fighting Breast Cancer on Your Lunch Break
Related Slides
 border=
Prostate Cancer
Uterine Cancer
Lung Cancer
Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Basal Cell Carcinoma
Bladder Cancer


This study looked at 15 patients with chronic hepatitis B (CHB) who underwent the local removal of a liver tumor known as a "single hepatocellular carcinoma" (HCC) that was less than four centimeters. HCC is the most common primary malignant tumor of the liver.

Six of the patients were diagnosed between 1991 and 1997, prior to the development of antiviral therapy. They were classified as historical controls.

The other nine were diagnosed between 2000 and 2004 and began ongoing antiviral therapy with lamivudine immediately after HCC diagnosis. In some cases, patients were also prescribed other antiviral medications, such as tenofovir and adefovir.

Median survival among patients who received antiviral therapy immediately after HCC diagnosis was 60 months, compared with 12.5 months for the historical control patients. Seven of the nine patients who began immediate antiviral therapy have not developed a new HCC or recurrence. The longest survivors have been cancer-free for more than 10 years.

"Before the antiviral drugs were developed, patients would often develop new lesions within a few months of tumor [removal] because we were not treating the underlying virus that is causing the cancer. The virus drives the cancer, and by suppressing the virus ... we can extend the survival of these patients," study author Dr. Hie-Won Hann, a professor of medicine at Jefferson Medical College of Thomas Jefferson University, said in a university news release.

Another option for patients with recurrent liver cancer is a liver transplant, which carries its own risk and is not always available.

Antiviral therapy, like virtually all therapies, is not risk-free. Common side effects of lamivudine, for example, include appetite loss, diarrhea, indigestion, and fatigue; more rare severe side effects that require immediate medical attention include a severe allergic reaction (rash, itching, chest tightness and swelling of the mouth, lips, face or tongue; dark urine; fast or irregular heartbeat; and yellowing of the eyes or skin.

The study was recently published in the International Journal of Cancer.

More information

The American Academy of Family Physicians has more about hepatitis B.

-- Robert Preidt

SOURCE: Thomas Jefferson University, June 24, 2010, news release

Copyright © 2010 HealthDay. All rights reserved.
Last updated 6/29/2010



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Feb 6, 2012
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: